Herbs (Global Traditional) · Jamu
Curcuma xanthorrhiza
Moderate Evidencebotanical
Hermetica Superfood Encyclopedia
Curcuma xanthorrhiza (Javanese turmeric) contains xanthorrhizol as its primary bioactive compound, which may support cholesterol management and provide antiviral effects. This traditional Jamu ingredient works through anti-inflammatory and lipid-modulating mechanisms in the body.
Curcuma xanthorrhiza (Javanese turmeric or temulawak) is a perennial herb native to Indonesia and Southeast Asia, belonging to the Zingiberaceae family. The rhizomes are harvested, dried, and typically extracted using ethanol or processed to isolate specific compounds like xanthorrhizol through chromatography.
Human clinical evidence is limited to two small trials: one RCT (PMID: 29445400) found no significant effects on SLE disease markers when combined with vitamin D3, while another study (PMID: 27365981) reported cholesterol-lowering effects in hypercholesterolemic patients. Most evidence comes from preclinical in vitro and animal studies examining antiviral, anticancer, and hepatoprotective effects.
No standardized human dosages are established from clinical trials. Preclinical studies used ethanol extracts at 2.5-125 μg/mL in vitro and xanthorrhizol at 8-32 μg/mL. The cholesterol study used an oral curcuminoid fraction, but exact dosage was not specified. Consult a healthcare provider before starting any new supplement.
Curcuma xanthorrhiza's primary compound xanthorrhizol appears to modulate cholesterol metabolism through hepatic enzyme regulation, though specific pathways require further elucidation. The antiviral activity against SARS-CoV-2 demonstrates viral inhibition at cellular level with IC50 values of 125 μg/mL in laboratory studies. Additional curcuminoids present may contribute to anti-inflammatory effects through COX and LOX pathway inhibition.
Limited human clinical evidence exists for Curcuma xanthorrhiza, with one study demonstrating cholesterol-lowering effects in hypercholesterolemic patients, though specific sample sizes and quantified outcomes are not publicly available. In vitro antiviral studies show promising activity against SARS-CoV-2 at 125 μg/mL concentrations, but human validation studies are absent. The current evidence base is preliminary and requires robust randomized controlled trials to establish clinical efficacy. Traditional use in Jamu medicine provides historical context but lacks systematic clinical documentation.
Safety data for Curcuma xanthorrhiza is limited, though it appears generally well-tolerated based on traditional use patterns in Indonesian medicine. Potential interactions with anticoagulant medications may occur due to curcuminoid content, similar to other Curcuma species. Gastrointestinal upset and allergic reactions are possible, particularly in sensitive individuals. Pregnancy and breastfeeding safety has not been established through clinical studies, warranting caution during these periods.